FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for SCEMBLIX (asciminib) from Novartis, expanding its label for chronic myeloid leukemia in patients who have failed pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

SUPPL AP for SCEMBLIX (ASCIMINIB)